Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for ...

Ever since the introduction of the Google Knowledge Graph, a growing number of organizations have adopted this powerful technology to drive efficiency and effectiveness in their data management.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

referring to the CagriSema data. “Was it a tolerability issue that stopped people from taking the highest dose, or was there something else?” Analysts aren’t expecting the earnings ...

“At the annual results next week, it would be really valuable to understand more on this,” said Paul Middleton, a global equities fund manager at Mirabaud Asset Management, referring to the CagriSema ...

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for CagriSema versus 11.8% with ...